A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Active, not recruiting · Phase 3 · NCT04810078
Conditions: Clear Cell Renal Cell Carcinoma
At a glance
- Research payments reported, 2025
- $64,255
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 681
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab and rHuPH20 (biological), Nivolumab (biological)
- Dates
- Started 2021-05-21; completion 2027-05-10
- Results posted
- Yes
The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $64,255 in research payments for this study in 2025 (1 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Health Research Incorporated $64,255
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.